Literature DB >> 16844842

A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.

Lana Klionsky1, Rami Tamir, Bob Holzinger, Xiaojuan Bi, Jane Talvenheimo, Helen Kim, Frank Martin, Jean-Claude Louis, James J S Treanor, Narender R Gavva.   

Abstract

Transient receptor potential vanilloid type 1 (TRPV1) can be activated by multiple chemical and physical stimuli such as capsaicin, anandamide, protons, and heat. Capsaicin interacts with the binding pocket constituted by transmembrane regions 3 and 4, whereas protons act through residues in the prepore loop of TRPV1. Here, we report on characterization of polyclonal and monoclonal antibodies to the prepore loop of TRPV1. A rabbit anti-rat TRPV1 polyclonal antibody (Ab-156H) acted as a full antagonist of proton activation (IC(50) values for pH 5 and 5.5 were 364.68 +/- 29.78 and 28.31 +/- 6.30 nM, respectively) and as a partial antagonist of capsaicin, heat, and pH 6 potentiated chemical ligand (anandamide and capsaicin) activation (50-79% inhibition). Ab-156H antagonism of TRPV1 is not affected by the conformation of the capsaicin-binding pocket because it is equally potent at wild-type (capsaicin-sensitive) rat TRPV1 and its T550I mutant (capsaicin-insensitive). With the goal of generating monoclonal antagonist antibodies to the prepore region of human TRPV1, we used a recently developed rabbit immunization protocol. Although rabbit polyclonal antiserum blocked human TRPV1 activation, rabbit monoclonal antibodies (identified on the basis of selective binding to Chinese hamster ovary cells expressing human TRPV1) did not block activation by either capsaicin or protons. Thus, rabbit polyclonal antibodies against rat and human TRPV1 prepore region seem to partially lock or stabilize the channel in the closed state, whereas rabbit anti-human TRPV1 monoclonal antibodies bind to the prepore region but do not lock or stabilize the channel conformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844842     DOI: 10.1124/jpet.106.108092

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models.

Authors:  Y A Andreev; S A Kozlov; E P Kozlovskaya; E V Grishin
Journal:  Dokl Biochem Biophys       Date:  2009 Jan-Feb       Impact factor: 0.788

2.  Production of a specific extracellular inhibitor of TRPM3 channels.

Authors:  J Naylor; C J Milligan; F Zeng; C Jones; D J Beech
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

3.  Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).

Authors:  Yaroslav A Andreev; Sergey A Kozlov; Sergey G Koshelev; Ekaterina A Ivanova; Margarita M Monastyrnaya; Emma P Kozlovskaya; Eugene V Grishin
Journal:  J Biol Chem       Date:  2008-06-25       Impact factor: 5.157

4.  Antibody therapeutics targeting ion channels: are we there yet?

Authors:  Han Sun; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-02       Impact factor: 6.150

Review 5.  Pain transduction: a pharmacologic perspective.

Authors:  Dan M McEntire; Daniel R Kirkpatrick; Nicholas P Dueck; Mitchell J Kerfeld; Tyler A Smith; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-05-23       Impact factor: 5.045

6.  Interdependent regulation of afferent renal nerve activity and renal function: role of transient receptor potential vanilloid type 1, neurokinin 1, and calcitonin gene-related peptide receptors.

Authors:  Chaoqin Xie; Jeffrey R Sachs; Donna H Wang
Journal:  J Pharmacol Exp Ther       Date:  2008-03-25       Impact factor: 4.030

Review 7.  Neurological perspectives on voltage-gated sodium channels.

Authors:  Niels Eijkelkamp; John E Linley; Mark D Baker; Michael S Minett; Roman Cregg; Robert Werdehausen; François Rugiero; John N Wood
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

8.  Hyaluronan modulates TRPV1 channel opening, reducing peripheral nociceptor activity and pain.

Authors:  Rebeca Caires; Enoch Luis; Francisco J Taberner; Gregorio Fernandez-Ballester; Antonio Ferrer-Montiel; Endre A Balazs; Ana Gomis; Carlos Belmonte; Elvira de la Peña
Journal:  Nat Commun       Date:  2015-08-27       Impact factor: 14.919

9.  Polypeptide modulators of TRPV1 produce analgesia without hyperthermia.

Authors:  Yaroslav A Andreev; Sergey A Kozlov; Yuliya V Korolkova; Igor A Dyachenko; Dmitrii A Bondarenko; Denis I Skobtsov; Arkadii N Murashev; Polina D Kotova; Olga A Rogachevskaja; Natalia V Kabanova; Stanislav S Kolesnikov; Eugene V Grishin
Journal:  Mar Drugs       Date:  2013-12-16       Impact factor: 5.118

10.  Antibodies to the extracellular pore loop of TRPM8 act as antagonists of channel activation.

Authors:  Silke Miller; Sara Rao; Weiya Wang; Hantao Liu; Judy Wang; Narender R Gavva
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.